Navigation Links
InterMune to Release Third Quarter Financial Results on October 28
Date:10/21/2010

BRISBANE, Calif., Oct. 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will release third quarter 2010 financial results on Thursday, October 28, 2010 at 4:00 p.m. Eastern time.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 20132776.  To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.  

A replay of the webcast and teleconference will be available approximately three hours after the call.  The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 20132776.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes pirfenidone for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  A Marketing Authorization Application (MAA) for pirfenidone is under review by the European Medicines Agency (EMA).  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About POCT ... is performed outside a clinical laboratory. It helps ... administrating appropriate treatments and medication. POCT is gaining ... of lifestyle diseases such as diabetes, heart disease, ... POCT devices are standardized to minimize errors during ...
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... , Sept. 18, 2014 ... of the "Global N-acetylcysteine Industry Report 2014" ... The Global N-acetylcysteine Industry Report 2014 is a ... of the global N-acetylcysteine industry. The ... including definitions, classifications, applications and industry chain structure. ...
(Date:9/18/2014)... 2014  U.S. biotech company Kultevat has ... for technology developed by the Donald Danforth Plant ... including for applications in production of natural rubber in ... was developed under the direction of Roger Beachy ... president of the Danforth Plant Science Center, and is ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2Kultevat obtains license of gene switch technology 2
... Offers Both Built-in ... Controls, INDIANAPOLIS, Oct. 29 Roche Diagnostics, ... and optional, external,liquid controls to help non-waived clinics ... for patients taking,blood thinner medication. The handheld, ...
... Surfaces Prompts Horizon Business Group To Spin-Off ... ... Ill., Oct. 29 Due to fast-growing global,demand for specially ... the,performance, aesthetics and durability of metal products and surfaces,Horizon Business ...
... Cliniqa Corporation (San,Marcos, CA), a manufacturer of ... acquisition of the primary assets of Reagents ... owned subsidiary of Hemagen,Diagnostics, Inc. (Columbia, MD). ... focusing on clinical chemistry reagents, calibrators,and controls. ...
Cached Biology Technology:Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services 2Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services 3Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services 4Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces 2Sureshield Coatings Company Established to Market Industry-Leading Portfolio of Advanced Coatings for Metal Surfaces 3Cliniqa Corporation Completes Asset Acquisition of Reagents Applications, Inc. 2
(Date:9/18/2014)... The global cycles of carbon and nitrogen comprise ... human and environmental systems have caused imbalances and ... greenhouse gases (GHGs). Increased GHGs result in climate ... terrestrial ecosystems, oceans and the atmosphere. Understanding these ... exciting branch of environmental science during the past ...
(Date:9/18/2014)... up to 400 kilometres in search of a home, which ... Clownfish spend their entire adult lives under the protection of ... open ocean, says study co-author, Dr Hugo Harrison from the ... at James Cook University. , "In the past we haven,t ... rare glimpse into how far they can swim, crossing large ...
(Date:9/17/2014)... doctoral student have designed a device based on a ... and dew., The device could provide water in drought-stricken ... Cheng Luo, professor in the Mechanical & Aerospace Engineering ... College of Engineering department, published "Bioinspired Plate-Based Fog Collectors" ... Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2Nemo's epic journey to find a new home 2Shorebird's beak inspires UT Arlington research on water collection 2
... Parkinson,s and Alzheimer,s is set to take a step ... analysis using automated 3D microscopy. An initiative ... the Eskitis Institute for Cellular and Molecular Biology, the ... of cells as complex as nerve cells in the ...
... study led by the University of North Carolina at Chapel ... 6 months in high-risk infants who later develop autism, compared ... a promising finding," said Jason J. Wolff, PhD, lead author ... Institute for Developmental Disabilities (CIDD). "At this point, it,s a ...
... at Oregon Health & Science University have ... supporting role actually are critically important for the growth ... has profound implications for the prevention and treatment of ... death in children aged one month to one year. ...
Cached Biology News:Brain-imaging differences evident at 6 months in infants who develop autism 2OHSU discovery may someday lead to prevention and treatment of sudden infant death syndrome 2
... The pWEB::TNC™ Deletion Cosmid Cloning Kit ... days, a complete and unbiased primary cosmid ... in making nested deletion sublibraries. High efficiency ... and highly reproducible kit protocols. First, genomic ...
... Disposable. Virgin, optically clear polystyrene with ... alphanumeric coordinates for cell counting. 100% ... is a new product number, created ... If showing no availability yet, please ...
Mouse monoclonal antibody raised against a partial recombinant AATK. NCBI Entrez Gene ID = AATK...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
Biology Products: